Skip to main content

Table 1 Patient characteristics at time of switch to second-line anti-retroviral regimen

From: An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Characteristic ATV/r LPV/r P value
Eligible 252 225  
Included, n (%) 224 (88.8) 205 (91.1) 0.663
Sex, n (%)
 Female 148 (66.1) 128 (62.4) 0.223
 Male 76 (33.9) 77 (37.6)
Age (years), median (IQR) 37 (30–42) 36 (31–42) 0.792
Grouped BMI, Kg/m2, n (%)a
 Under weight 15 (6.9) 21 (11.4) 0.305
 Normal 137 (63.4) 111 (60.0)
 Over weight 64 (29.6) 53 (28.7)
 Missing 8 20
First-line drug, n (%)
 NVP 144 (64.3) 132 (64.4) 0.982
 EFV 80 (35.7) 73 (35.6)
CD4 count cell/μl, median (IQR) 118 (59–214) 102 (59–189) 0.088
Viral load Log 10 copies/ml at switch to second- line, median (IQR) 4.5 (3.8–4.9) 4.5 (3.2–5.1) 0.421
Duration (months) on first-line therapy, median (IQR) 56 (28–80) 46 (25–67) 0.025
Duration (months on second-line by time of viral load, median (IQR) 19 (21–25) 40 (32–52) < 0.001
NRTI drugs in second line, n (%)
 3TC-TDF 191 (85.3) 154 (75.1) 0.741
 3TC-AZT 29 (12.9) 48 (23.4)
 3TC-ABC 4 (1.8) 3 (1.5)
  1. aBMI was categorized as Underweight (< 18.5 Kg/m2), Normal (18.5–24.9 Kg/m2),
  2. Over weight (≥25.0) Kg/m2